Oxbow Advisors LLC Purchases 4,790 Shares of Sanofi (NASDAQ:SNY)

Oxbow Advisors LLC lifted its position in Sanofi (NASDAQ:SNY) by 4.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 104,749 shares of the company’s stock after purchasing an additional 4,790 shares during the quarter. Oxbow Advisors LLC’s holdings in Sanofi were worth $5,052,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in SNY. Synergy Asset Management LLC bought a new stake in Sanofi during the fourth quarter worth approximately $25,000. McClarren Financial Advisors Inc. increased its stake in Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after acquiring an additional 543 shares during the last quarter. Concord Wealth Partners increased its stake in Sanofi by 157.8% during the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after acquiring an additional 363 shares during the last quarter. Fortitude Family Office LLC increased its stake in Sanofi by 708.6% during the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after acquiring an additional 659 shares during the last quarter. Finally, Sunbelt Securities Inc. increased its stake in Sanofi by 72.1% during the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after acquiring an additional 313 shares during the last quarter. 14.04% of the stock is owned by institutional investors.

Sanofi Trading Up 0.6 %

SNY opened at $54.46 on Friday. The stock has a market cap of $138.21 billion, a price-to-earnings ratio of 21.87, a P/E/G ratio of 1.01 and a beta of 0.57. The stock’s 50 day moving average price is $50.95 and its 200-day moving average price is $52.52. Sanofi has a one year low of $45.22 and a one year high of $58.97. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, equities analysts forecast that Sanofi will post 4.36 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on SNY. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Finally, StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Sanofi currently has a consensus rating of “Buy” and a consensus target price of $60.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.